In general, glycemic control is an accepted concept in TBI management [27, 38], and supplementation with additional substrates such as lactate (intravenously or via CMD) may also show some clinical utility in reducing complications, like intracranial hypertension [44], when metabolic targets are better defined
Individuals who are overweight or obese (with a BMI of 25 or higher) or have one or more obesity-related conditions may be suitable candidates for GLP-1 therapy
Notably, multiple clinical experiments show that systolic blood pressure (SBP) is decreased by GLP-1R agonists in T2DM hypertensive patients while DBP is less affected (92, 97, 98)
For now, and in the context of GLP therapy, it will be important to first better understand the insulin release and response kinetics in normal weight, nondiabetic patients before recommending these meds for a broader population.
ABIN6757400 100 g Catalog No